Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA.

Cancer Res. 2008 Jun 1;68(11):4183-91. doi: 10.1158/0008-5472.CAN-08-0413.

2.

RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.

De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erreni M, Pelicci G, Santoro M, Melillo RM.

Oncogene. 2005 Sep 15;24(41):6303-13.

PMID:
15940252
3.

Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.

Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, Fagin JA.

Mol Endocrinol. 2003 Jul;17(7):1425-36. Epub 2003 Apr 10.

PMID:
12690093
4.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

5.

The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.

Wang C, Mayer JA, Mazumdar A, Brown PH.

Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.

6.

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

Knauf JA, Kuroda H, Basu S, Fagin JA.

Oncogene. 2003 Jul 10;22(28):4406-12.

PMID:
12853977
7.

BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.

PMID:
16254036
8.

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.

Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM.

BMC Cancer. 2008 May 23;8:144. doi: 10.1186/1471-2407-8-144.

9.

Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.

Puxeddu E, Mitsutake N, Knauf JA, Moretti S, Kim HW, Seta KA, Brockman D, Myatt L, Millhorn DE, Fagin JA.

J Biol Chem. 2003 Dec 26;278(52):52131-8. Epub 2003 Oct 10.

10.

Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.

Henderson YC, Fredrick MJ, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2007 Aug;133(8):810-5.

PMID:
17709622
11.

Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I.

Mol Carcinog. 2009 Mar;48(3):220-31. doi: 10.1002/mc.20474.

PMID:
18756447
12.

High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.

Fiore AP, Fuziwara CS, Kimura ET.

Thyroid. 2009 Nov;19(11):1249-56. doi: 10.1089/thy.2008.0408.

PMID:
19725779
13.

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2006 Jun 15;66(12):6280-7.

14.

The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.

Rusciano MR, Salzano M, Monaco S, Sapio MR, Illario M, De Falco V, Santoro M, Campiglia P, Pastore L, Fenzi G, Rossi G, Vitale M.

Endocr Relat Cancer. 2010 Jan 29;17(1):113-23. doi: 10.1677/ERC-09-0214. Print 2010 Mar.

15.

RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.

Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M.

Mol Endocrinol. 2003 Jul;17(7):1382-94. Epub 2003 May 8.

PMID:
12738763
16.

Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.

Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M.

Mol Endocrinol. 2004 Nov;18(11):2672-84. Epub 2004 Aug 5.

PMID:
15297606
17.

An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway.

Santoro M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A, di Fiore PP.

Mol Cell Biol. 1994 Jan;14(1):663-75.

18.

Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.

Frasca F, Vella V, Nicolosi ML, Messina RL, Gianì F, Lotta S, Vigneri P, Regalbuto C, Vigneri R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2502-12. doi: 10.1210/jc.2012-3623. Epub 2013 Apr 4.

PMID:
23559083
19.

Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).

Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, Shong M.

Mol Endocrinol. 2007 Dec;21(12):3039-49. Epub 2007 Aug 30.

PMID:
17761947
20.

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2007 Jan 1;67(1):381-90.

Supplemental Content

Support Center